Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZYLBB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ZW-33
|
|||||
| Synonyms |
ZW 33; ZW33
Click to Show/Hide
|
|||||
| Organization |
Zymeworks Biopharmaceuticals, Inc.; Zymeworks BC, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
Gastric cancer [ICD11:2B72]
Clinical candidate
Ovarian cancer [ICD11:2C73]
Clinical candidate
|
|||||
| Antibody Name |
Zanidatamab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Special Approval(s) |
Orphan drug(FDA)
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.